10 completed. 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 10 |
Follow WCCT Global: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MT1013 Clinical TRIAL In Healthy Subject MT1013 - Healthy Volunteer | Phase 1 | Completed | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 40 | 2021-06-28 | 2022-07-29 |
| Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule - Type1 Diabetes | Phase 1 | Completed | Immunomolecular Therapeutics, Inc. | 30 | 2020-11-09 | 2021-08-25 |
| Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model Norwalk GI.1 Virus - Norovirus Infection | Phase 1 | Completed | WCCT Global | 16 | 2018-10-03 | 2020-01-22 |
| Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients TLD1433 infusion and photodynamic therapy (PDT) treatment - Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG | Phase 1 | Completed | Theralase® Technologies Inc. | 6 | 2016-12-21 | 2018-08-20 |
| Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris SB204 4% - Acne Vulgaris | Phase 1 | Completed | Novan, Inc. | 18 | 2016-06-07 | 2018-10-12 |
| Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administered Under Fed Conditions in Healthy Chinese Volunteers Aramchol, Placebo - Healthy Volunteers | Phase 1 | Completed | Galmed Pharmaceuticals Ltd | 64 | 2016-05-01 | 2016-12-21 |
| Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose) NGP 555 - Alzheimer's Disease | Phase 1 | Completed | NeuroGenetic Pharmaceuticals Inc | 24 | 2016-01-01 | 2017-03-29 |
| Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042) PUL-042 Inhalation Solution, Cromolyn Sodium, Albuterol sulfate - Healthy | Phase 1 | Completed | Pulmotect, Inc. | 16 | 2015-07-01 | 2017-08-10 |
| Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus Live, wild-type A/California/H1N1 2009 influenza virus - Influenza | Phase 1 | Completed | WCCT Global | 35 | 2015-01-19 | 2020-01-14 |
| Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers MOD-4023, Placebo - Growth Hormone Deficiency | Phase 1 | Completed | OPKO Health, Inc. | 42 | 2015-01-01 | 2019-09-30 |
Acne Vulgaris (1) · Alzheimer Disease (1) · Autoimmune Diseases (1) · Caliciviridae Infections (1) · Carcinoma, Transitional Cell (1) · Diabetes Mellitus (1) · Dwarfism, Pituitary (1) · Influenza, Human (1) · Non-Muscle Invasive Bladder Neoplasms (1)
1-phenyl-3,3-dimethyltriazene (1) · Albuterol (1) · BID protein, human (1) · Capsules (1) · Cromolyn Sodium (1) · MOD-4023 (1) · Photochemotherapy (1) · Therapeutics (1) · aramchol (1) · berdazimer sodium (1) · microcrystalline cellulose (1)
United States (8) · Canada (1)
Apinya Vutikkilaird, DO (1) · Girish Kulkarni, MD, PhD (1) · M. Joyce Rico, MD (1) · Michelle Ababa, MD (1)